Aptorum Group Limited's SEC filings document its foreign private issuer reporting, corporate governance and capital-structure disclosures. Form 6-K reports include annual general meeting proxy materials, shareholder voting results, board-election items, auditor ratification matters and disclosures tied to Class A Ordinary Shares and Class B Ordinary Shares.
The company's filings also cover material-event reports, material agreements, operating and financial results, registration-statement references on Form S-8 and Form F-3, and Nasdaq listing-compliance notices. These records frame APM's pharmaceutical development business alongside its governance, share structure, risk factors and public-company reporting obligations.
Aptorum Group Limited submitted a Form 6-K to provide its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, along with a related operating and financial review. These materials give an updated picture of the company’s mid‑year financial position and performance.
The company is also incorporating these interim financial statements into its existing Form S-8 and Form F-3 registration statements, so the new information becomes part of those offering documents. The filing further lists key agreements related to its previously disclosed transaction with DiamiR, including a merger agreement, management services agreement, intellectual property license, voting and support agreement, and a form of stockholders agreement, plus the associated Inline XBRL data files.
Aptorum Group Limited filed a 6-K updating investors on its planned merger with DiamiR Biosciences Corp.. Under the previously announced Agreement and Plan of Merger, Aptorum will form a Delaware subsidiary that will merge into DiamiR, leaving DiamiR as a wholly owned subsidiary of Aptorum. The filing notes that later this week DiamiR will present at the HCW Conference, using a presentation about both companies and the merger, which is furnished as Exhibit 99.1.